Home
 

Pharmacy Benefits Management

 
January 22, 2015 | Anthony Brino

The nation's third largest insurer is the latest to find a cheaper way to bring a curative therapy to members with Hepatitis C.


January 14, 2015 | Anthony Brino

If 2014 was a year of managing member populations who need a blockbuster treatment for hepatitis C, 2015 is turning out to be one of deals for everyone to access that drug.


January 8, 2015 | Anthony Brino

More affordability may be coming to the surging speciality pharmaceuticals space, as regulators move to approve the first generic-equivalent version of a biologic drug.


January 7, 2015 | Anthony Brino

Competition for treating America's hepatitis C population is intensifying among pharmaceutical companies and benefits management firms, suggesting a thaw in the $1,000 per-pill price of last year's blockbuster.


December 22, 2014 | Anthony Brino

In the war for affordably treating the hepatis C liver virus, pharmacy benefits managers are fighting back now that alternatives are becoming available.


December 11, 2014 | Anthony Brino

The latest salvo in the pharmaceutical price wars is being launched from an unlikely outpost, but one that represents the struggle to pay for the year's most successful drug.


December 8, 2014 | Anthony Brino

Amid an intense debate about the cost and value of drugs, a big payer and a big pharma company are promising to comb through their collective evidence and deliver new knowledge that may improve patient outcomes.


November 10, 2014 | Anthony Brino

Pre-reform underwriting approaches for speciality medications like HIV/AIDS drugs are not going to fly in the new health insurance market, as regulators and patient advocates intervene to challenge a range of practices.


October 13, 2014 | Rich Pizzi

Cost-sharing in traditional Medicare is on the rise, and benefit designs in Medicare drug plans are changing.


October 10, 2014 | Anthony Brino

The new hepatitis C treatment Sovaldi has driven debate over drug costs for close to a year, but it’s also been a case study in access and coverage in public payer programs.


October 3, 2014 | Anthony Brino

Drug benefits stand as some of the most consequential consumer confusions that can arise in public exchanges, increasing the onus on insurers to improve the design and explanation of formularies.


September 23, 2014 | Anthony Brino

A shrinking number of Medicare Part D drug plans is set to bring beneficiaries some more low-cost choices, but also some potentially confusing benefit designs.


Advertisement. Closing in 15 seconds.